演題抄録

FACO Poster Session

開催概要
開催回
第56回・2018年・横浜
 

Preparation and evaluation study of Cy754-Rituximab: A new receptor-targeted tracer for sentinel lymph node in animal model

演題番号 : FP1-4

[筆頭演者]
Speaker)Binbin Cong:1 
[共同演者]
Xiaoshan Cao:1、Yongsheng Wang:1、Jinming Yu:2

1:Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, China、2:Department of Radiation Oncology, Institut Curie, France

 

Purpose: Cy754 was combined with Rituximab to prepare a new receptor-targeted tracer for sentinel lymph node (SLN). The appropriate combination ratio of the tracer was identified, the biological property and safety limitation was tested, and the SLN imaging ability of the new tracer was evaluated.
Experimental Design: Cy754 was combined directly with Rituximab to prepare Cy754-Rituximab. After centrifugation and purifying, the labeled rate was analyzed by instant thin-layer chromatography-silica gel, the molecular integrity was tested by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the molecular immune activity was tested by ELLAS. After the acute toxicity and the local toxicity tested, the SLN localization ability of the tracer was evaluated in the SLN animal model.
Results: Rituximab was intact and kept the immune activity in the new tracer. The Cy754 labeled rate of Rituximab was 100%. The new tracer was bacteria and pyogen free, and was no toxicity to mice with local injection. After Cy754-Rituximab injection, the fluorescence imaging SLN could find in the SLN animal model. The SLN imagines were stable and clear for 10 hours. The location of SLN identified by the new tracer was accorded with the standard radiotracer.
Conclusions: The produce method of the new receptor-targeted tracer for SLN is simple, effective, and no radioactive burden. The new tracer was safe with local injection. It could make only SLN imaging with appropriate injection dose and could be used in the study of SLN.

キーワード

臓器別:Breast

手法別:Imaging

前へ戻る